Mario Raviglione on Coordinating Research to End TB

Coordinating new TB treatments and diagnostics, and a sustainable approach to End TB



Martha Brumfield on the Success and Continued Growth of CPTR

How CPTR has grown into a vital and innovative catalyst in the fight against TB


US NIAID’s Anthony Fauci on Halting Drug Resistance

New TB drug regimens and diagnostics are needed to fight TB and MDR-TB


EMA’s Hans-Georg Eichler on Innovation Within Regulation

Instead of gatekeepers, regulators must act as enablers of innovation



New publication highlights CPTR’s work on Hollow Fiber System Model for TB

The achievements and ongoing efforts of CPTR’s work on the Hollow Fiber System Model for TB (HFS-TB) are detailed in a new supplement published in the Clinical Infectious Diseases journal. The supplement includes an editorial by EMA on its qualification of this tool to reliably assess the potential efficacy of new drugs and combination regimens, […]

August 13, 2015 Drug Development drug development hollow fiber model

View webinar on Good Participatory Practice Guidelines for TB Drug Trials

Recently, CPTR partners hosted and participated in a webinar covering Good Participatory Practice (GPP) Guidelines for TB Drug Trials. GPP focuses on effectively engaging all stakeholders within the design and conduct of medical research. It can accelerate the pace of trials, prevent conflicts, and support the introduction of new products. The event covered best practices […]

July 23, 2015 Research Resources

From the Working Groups

Modeling & Simulation Workgroup Q2-2015 Update

Working closely with the Data Standards and Integration Workgroup (DSI-WG), the M&S-WG uses aggregated clinical trial data to create robust empirical, mechanistic, and systems biology models and quantitative simulation tools to facilitate TB drug and drug regimen development.

July 1, 2015

Data Standards & Integration Workgroup Q2-2015 Update

The DSI-WG provides the information technology (IT) infrastructure to support all CPTR data needs for developing regulatory science tools and methods to enable development of new TB drugs, drug regimens, and diagnostics. A key focus is aggregating all relevant data in a secure database for analysis by the CPTR Workgroups and authorized researchers. The DSI-WG […]

July 1, 2015

Pre-Clinical and Clinical Sciences Workgroup Q2-2015 Update

The PCS-WG is focused on the evidence-based evaluation of translational tools that support the effective decision making to advance new agents from the pre-clinical to clinical development space. These tools represent innovative approaches to address pre-clinical issues, including pre-clinical in vitro and in vivo efficacy, pre-clinical drug safety, and toxicology, pre-clinical PK/PD analyses involving the […]

July 1, 2015
About CPTR

Through partnership, CPTR speeds the development of new and markedly improved drug regimens for tuberculosis.